These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 8862702)

  • 1. Treatment of advanced breast cancer: current status.
    Piccart M
    Anticancer Drugs; 1996 Aug; 7 Suppl 2():5-7. PubMed ID: 8862702
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Docetaxel (Taxotere) for the treatment of anthracycline-resistant breast cancer.
    Ravdin PM
    Semin Oncol; 1997 Aug; 24(4 Suppl 10):S10-18-S10-21. PubMed ID: 9275002
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Therapy of anthracycline-resistant metastatic breast carcinoma].
    Kreienberg R
    Praxis (Bern 1994); 1998 Apr; 87(17):573-7. PubMed ID: 9623323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Docetaxel in anthracycline-resistant metastatic breast cancer.
    Hui YF; Ignoffo RJ
    Cancer Pract; 1997; 5(2):124-7. PubMed ID: 9110651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Docetaxel (Taxotere): an effective agent in the management of second-line breast cancer.
    van Oosterom AT
    Semin Oncol; 1995 Dec; 22(6 Suppl 13):22-8. PubMed ID: 8604449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Taxoids: effective agents in anthracycline-resistant breast cancer.
    Ravdin PM
    Semin Oncol; 1995 Dec; 22(6 Suppl 13):29-34. PubMed ID: 8604450
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging role of docetaxel (Taxotere) in the adjuvant therapy of breast cancer.
    Ravdin PM
    Semin Oncol; 1999 Jun; 26(3 Suppl 9):20-3. PubMed ID: 10426455
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Docetaxel and paclitaxel in breast cancer therapy: present status and future prospects.
    D'Andrea GM; Seidman AD
    Semin Oncol; 1997 Aug; 24(4 Suppl 13):S13-27-S13-44. PubMed ID: 9335514
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I-II studies of docetaxel as a single agent in the treatment of metastatic breast cancer.
    Trudeau ME
    Semin Oncol; 1999 Jun; 26(3 Suppl 8):21-6. PubMed ID: 10403470
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First-line treatment of metastatic breast cancer.
    Trudeau ME
    Anticancer Drugs; 1996 Aug; 7 Suppl 2():9-12. PubMed ID: 8862703
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A review of the efficacy and safety of docetaxel as monotherapy in metastatic breast cancer.
    Crown J
    Semin Oncol; 1999 Feb; 26(1 Suppl 3):5-9. PubMed ID: 10203264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evolution in the treatment of advanced breast cancer.
    Crown J
    Semin Oncol; 1998 Oct; 25(5 Suppl 12):12-7. PubMed ID: 9865706
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reflections on the development of resistance during therapy for advanced breast cancer. Implications of high levels of activity of docetaxel in anthracycline-resistant breast cancer patients.
    Ravdin PM
    Eur J Cancer; 1997 Aug; 33 Suppl 7():S7-10. PubMed ID: 9486096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paclitaxel and docetaxel in breast and ovarian cancer.
    Drug Ther Bull; 1997 Jun; 35(6):43-6. PubMed ID: 9282422
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Taxanes in the treatment of breast cancer: a prodigy comes of age.
    Miller KD; Sledge GW
    Cancer Invest; 1999; 17(2):121-36. PubMed ID: 10071597
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A clinical study of taxotere versus taxotere plus the antiprolactinemic agent bromocriptine in metastatic breast cancer pretreated with anthracyclines.
    Lissoni P; Bucovec R; Malugani F; Ardizzoia A; Villa S; Gardani GS; Vaghi M; Tancini G
    Anticancer Res; 2002; 22(2B):1131-4. PubMed ID: 12168912
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of patients resistant to anthracycline therapy.
    Ravdin PM
    Anticancer Drugs; 1996 Aug; 7 Suppl 2():13-6. PubMed ID: 8862704
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single-agent docetaxel (Taxotere) in randomized phase III trials.
    Burris HA
    Semin Oncol; 1999 Jun; 26(3 Suppl 9):1-6. PubMed ID: 10426452
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Future perspectives of docetaxel (Taxotere) in front-line therapy.
    Piccart MJ; Di Leo A
    Semin Oncol; 1997 Aug; 24(4 Suppl 10):S10-27-S10-33. PubMed ID: 9275004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Docetaxel in the treatment of breast cancer: current experience and future prospects.
    Nabholtz JM; Gligorov J
    Expert Rev Anticancer Ther; 2005 Aug; 5(4):613-33. PubMed ID: 16111463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.